{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:53:46Z","timestamp":1794282826646,"version":"4.9.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41581-025-00996-5","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:01:56Z","timestamp":1758272516000},"page":"727-735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Two decades of nephrology research: progress and future challenges"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3298-8642","authenticated-orcid":false,"given":"Urmila","family":"Anandh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Joachim","family":"Anders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0578-2529","authenticated-orcid":false,"given":"Justine","family":"Bacchetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3460","authenticated-orcid":false,"given":"David W","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7066-8135","authenticated-orcid":false,"given":"Valerie","family":"Luyckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6194-3446","authenticated-orcid":false,"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5284-2440","authenticated-orcid":false,"given":"Bernardo","family":"Rodriguez-Iturbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1005-3726","authenticated-orcid":false,"given":"Katalin","family":"Susztak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0339-9008","authenticated-orcid":false,"given":"Motoko","family":"Yanagita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"996_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41597-019-0351-8","volume":"7","author":"J Liao","year":"2020","unstructured":"Liao, J. et al. Single-cell RNA sequencing of human kidney. Sci. Data 7, 4 (2020).","journal-title":"Sci. Data"},{"key":"996_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1056\/NEJMoa2410659","volume":"393","author":"R Agarwal","year":"2025","unstructured":"Agarwal, R. et al. Finerenone with empagliflozin in chronic kidney disease and type 2 diabetes. N. Engl. J. Med. 393, 533\u2013543 (2025).","journal-title":"N. Engl. J. Med."},{"key":"996_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-021-01872-8","volume":"16","author":"G Bassanese","year":"2021","unstructured":"Bassanese, G., Wlodkowski, T., Servais, A., Heidet, L., Roccatello, D. & Emma, F. et al. The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet. J. Rare Dis. 16, 251 (2021).","journal-title":"Orphanet. J. Rare Dis."},{"key":"996_CR4","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41581-024-00864-8","volume":"20","author":"MSY Ng","year":"2024","unstructured":"Ng, M. S. Y., Kaur, G., Francis, R. S., Hawley, C. M. & Johnson, D. W. Drug repurposing for glomerular diseases: an underutilized resource. Nat. Rev. Nephrol. 20, 707\u2013721 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"996_CR5","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1186\/s12882-022-02827-2","volume":"23","author":"G Ashuntantang","year":"2022","unstructured":"Ashuntantang, G., Miljeteig, I. & Luyckx, V. A. Bedside rationing and moral distress in nephrologists in sub-Saharan Africa. BMC Nephrol. 23, 196 (2022).","journal-title":"BMC Nephrol."},{"key":"996_CR6","unstructured":"World Health Organization. Reducing the burden of noncommunicable diseases through promotion of kidney health and strengthening prevention and control of kidney disease. WHO https:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/EB156\/B156_(20)-en.pdf (accessed 10 February 2025)."},{"key":"996_CR7","unstructured":"World Heart Federation. Driving sustainable action for circulatory health: white paper on circulatory health. World Heart Federation https:\/\/world-heart-federation.org\/resource\/white-paper-for-circulatory-health\/drivingsustainableactionforcirculatoryhealth (2018)."},{"key":"996_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-074216","volume":"383","author":"TK Chen","year":"2023","unstructured":"Chen, T. K. et al. Advances in the management of chronic kidney disease. BMJ 383, e074216 (2023).","journal-title":"BMJ"},{"key":"996_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","volume":"361","author":"LH Beck","year":"2009","unstructured":"Beck, L. H. et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N. Engl. J. Med. 361, 11\u201321 (2009).","journal-title":"N. Engl. J. Med."},{"key":"996_CR10","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","volume":"360","author":"G Remuzzi","year":"2002","unstructured":"Remuzzi, G. et al. Rituximab for idiopathic membranous nephropathy. Lancet 360, 923\u2013924 (2002).","journal-title":"Lancet"},{"key":"996_CR11","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/nrneph.2012.195","volume":"8","author":"M Noris","year":"2012","unstructured":"Noris, M., Mescia, F. & Remuzzi, G. STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nat. Rev. Nephrol. 8, 622\u2013633 (2012).","journal-title":"Nat. Rev. Nephrol."},{"key":"996_CR12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajt.2024.03.001","volume":"24","author":"LC Pullen","year":"2024","unstructured":"Pullen, L. C. Xenotransplantation moves toward clinical trials. Am. J. Transplant. 24, 509\u2013511 (2024).","journal-title":"Am. J. Transplant."},{"key":"996_CR13","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2215\/CJN.09380822","volume":"18","author":"BF Palmer","year":"2022","unstructured":"Palmer, B. F. & Clegg, D. J. Kidney-protective effects of SGLT2 inhibitors. Clin. J. Am. Soc. Nephrol. 18, 279\u2013289 (2022).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"996_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2022.100435","volume":"4","author":"PM Devarajan","year":"2022","unstructured":"Devarajan, P. M. et al. Emerging role of clinical genetics in CKD. Kidney Med. 4, 100435 (2022).","journal-title":"Kidney Med."},{"key":"996_CR15","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.humimm.2021.02.012","volume":"82","author":"T Hu","year":"2021","unstructured":"Hu, T., Chitnis, N., Monos, D. & Dinh, A. Next-generation sequencing technologies: an overview. Hum. Immunol. 82, 801\u2013811 (2021).","journal-title":"Hum. Immunol."},{"key":"996_CR16","unstructured":"World Health Organization. Hypertension. WHO https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension (accessed 27 February 2025)."},{"key":"996_CR17","doi-asserted-by":"publisher","first-page":"eadp4753","DOI":"10.1126\/science.adp4753","volume":"387","author":"H Liu","year":"2025","unstructured":"Liu, H. et al. Kidney multiome-based genetic scorecard reveals convergent coding and regulatory variants. Science 387, eadp4753 (2025).","journal-title":"Science"},{"key":"996_CR18","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1126\/science.aar2131","volume":"360","author":"J Park","year":"2018","unstructured":"Park, J. et al. Single-cell transcriptomics of the mouse kidney reveals potential cellular targets of kidney disease. Science 360, 758\u2013763 (2018).","journal-title":"Science"},{"key":"996_CR19","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","volume":"619","author":"BB Lake","year":"2023","unstructured":"Lake, B. B. et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 619, 585\u2013594 (2023).","journal-title":"Nature"},{"key":"996_CR20","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1038\/s41588-024-01802-x","volume":"56","author":"A Abedini","year":"2024","unstructured":"Abedini, A. et al. Single-cell multi-omic and spatial profiling of human kidneys implicates the fibrotic microenvironment in kidney disease progression. Nat. Genet. 56, 1712\u20131724 (2024).","journal-title":"Nat. Genet."},{"key":"996_CR21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","volume":"149","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria. Circulation 149, 450\u2013462 (2024).","journal-title":"Circulation"},{"key":"996_CR22","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMp1805097","volume":"379","author":"JS Berns","year":"2018","unstructured":"Berns, J. S., Glickman, A. & McCoy, M. S. Dialysis-facility joint-venture ownership \u2014 hidden conflicts of interest. N. Engl. J. Med. 379, 1295\u20131297 (2018).","journal-title":"N. Engl. J. Med."},{"key":"996_CR23","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1056\/NEJMoa1310799","volume":"370","author":"EW Gregg","year":"2014","unstructured":"Gregg, E. W. et al. Changes in diabetes-related complications in the United States, 1990\u20132010. N. Engl. J. Med. 370, 1514\u20131523 (2014).","journal-title":"N. Engl. J. Med."},{"key":"996_CR24","doi-asserted-by":"publisher","first-page":"1038\u20131040","DOI":"10.1016\/j.kint.2023.03.018","volume":"103","author":"B Ranchin","year":"2023","unstructured":"Ranchin, B. et al. Devices for long-term hemodialysis in small children \u2014 a plea for action. Kidney Int. 103, 1038\u20131040 (2023).","journal-title":"Kidney Int"},{"key":"996_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf035","author":"LJ Deesker","year":"2025","unstructured":"Deesker, L. J. et al. Global access to management of primary hyperoxaluria: a survey on behalf of OxalEurope, G&K working group of the ERA, and ESPN. Nephrol. Dial. Transplant. https:\/\/doi.org\/10.1093\/ndt\/gfaf035 (2025).","journal-title":"Nephrol. Dial. Transplant."},{"key":"996_CR26","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jama.2023.4387","volume":"329","author":"R Rubin","year":"2023","unstructured":"Rubin, R. It takes an average of 17 years for evidence to change practice \u2014 the burgeoning field of implementation science seeks to speed things up. JAMA 329, 1333\u20131336 (2023).","journal-title":"JAMA"},{"key":"996_CR27","first-page":"100988","volume":"43","author":"BL Neuen","year":"2024","unstructured":"Neuen, B. L. et al. Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data. Lancet Reg. Health West Pac. 43, 100988 (2024).","journal-title":"Lancet Reg. Health West Pac."},{"key":"996_CR28","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1001\/jamainternmed.2018.3931","volume":"178","author":"TJ Moore","year":"2018","unstructured":"Moore, T. J., Zhang, H., Anderson, G. & Alexander, G. C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US food and drug administration, 2015\u20132016. JAMA Intern. Med. 178, 1451\u20131457 (2018).","journal-title":"JAMA Intern. Med."},{"key":"996_CR29","first-page":"262","volume":"26","author":"Tolvaptan (Jinarc) and polycystic kidney disease","year":"2017","unstructured":"Tolvaptan (Jinarc) and polycystic kidney disease. Too many adverse effects, uncertain efficacy. Prescrire Int. 26, 262 (2017).","journal-title":"Prescrire Int."},{"key":"996_CR30","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","volume":"403","author":"GBD 2021 Causes of Death Collaborators.","year":"2024","unstructured":"GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403, 2100\u20132132 (2024).","journal-title":"Lancet"},{"key":"996_CR31","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1016\/S0140-6736(25)00548-3","volume":"405","author":"R Lou-Meda","year":"2025","unstructured":"Lou-Meda, R. & P\u00e9rez, J. B. Reducing the burden of chronic kidney disease in the world. Lancet 405, 1810 (2025).","journal-title":"Lancet"},{"key":"996_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.kint.2023.03.007","volume":"104","author":"M Nangaku","year":"2023","unstructured":"Nangaku, M. et al. International Society of Nephrology first consensus guidance for preclinical animal studies in translational nephrology. Kidney Int. 104, 36\u201345 (2023).","journal-title":"Kidney Int"},{"key":"996_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1056\/NEJMra2308577","volume":"391","author":"A Vivante","year":"2024","unstructured":"Vivante, A. Genetics of chronic kidney disease. N. Engl. J. Med. 391, 627\u2013639 (2024).","journal-title":"N. Engl. J. Med."},{"key":"996_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41581-024-00861-x","volume":"20","author":"P Tasca","year":"2024","unstructured":"Tasca, P. et al. Application of spatial-omics to the classification of kidney biopsy samples in transplantation. Nat. Rev. Nephrol. 20, 755\u2013766 (2024).","journal-title":"Nat. Rev. Nephrol."},{"key":"996_CR35","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1016\/j.kint.2024.01.012","volume":"105","author":"A Reznichenko","year":"2024","unstructured":"Reznichenko, A. et al. Unbiased kidney-centric molecular categorization of chronic kidney disease as a step towards precision medicine. Kidney Int 105, 1263\u20131278 (2024).","journal-title":"Kidney Int"},{"key":"996_CR36","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1053\/j.ajkd.2024.10.015","volume":"85","author":"FP Wieringa","year":"2025","unstructured":"Wieringa, F. P. et al. The future of technology-based kidney replacement therapies: an update on portable, wearable, and implantable artificial kidneys. Am. J. Kidney Dis. 85, 787\u201396 (2025).","journal-title":"Am. J. Kidney Dis."},{"key":"996_CR37","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s12882-025-03968-w","volume":"26","author":"P Torabinavid","year":"2025","unstructured":"Torabinavid, P., Khosropanah, M. H., Azimzadeh, A. & Kajbafjadeh, A.-M. Current strategies on kidney regeneration using tissue engineering approaches: a systematic review. BMC Nephrol. 26, 66 (2025).","journal-title":"BMC Nephrol."},{"key":"996_CR38","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha, D. et al. 2010 Rheumatoid Arthritis Classification Criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569\u20132581 (2010).","journal-title":"Arthritis Rheum"},{"key":"996_CR39","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/s41577-022-00816-y","volume":"23","author":"HJ Anders","year":"2023","unstructured":"Anders, H. J., Kitching, A. R., Leung, N. & Romagnani, P. Glomerulonephritis: immunopathogenesis and immunotherapy. Nat. Rev. Immunol. 23, 453\u2013471 (2023).","journal-title":"Nat. Rev. Immunol."},{"key":"996_CR40","doi-asserted-by":"publisher","first-page":"907\u2013909","DOI":"10.1093\/ndt\/gfae029","volume":"39","author":"O Gross","year":"2024","unstructured":"Gross, O., Haffner, D., Schaefer, F. & Weber, L. T. SGLT2 inhibitors: approved for adults and cats but not for children with CKD. Nephrol. Dial. Transplant. 39, 907\u2013909 (2024).","journal-title":"Nephrol. Dial. Transplant."},{"key":"996_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12939-022-01715-3","volume":"21","author":"JT Ashu","year":"2022","unstructured":"Ashu, J. T. et al. Challenges to the right to health in sub-Saharan Africa: reflections on inequities in access to dialysis for patients with end-stage kidney failure. Int. J. Equity Health 21, 126 (2022).","journal-title":"Int. J. Equity Health"},{"key":"996_CR42","unstructured":"Silverstein, A. My transplanted heart and I will die soon. The New York Times (2023)."},{"key":"996_CR43","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1056\/NEJMoa2201422","volume":"387","author":"BP Griffith","year":"2022","unstructured":"Griffith, B. P. et al. Genetically modified porcine-to-human cardiac xenotransplantation. N. Engl. J. Med. 387, 35\u201344 (2022).","journal-title":"N. Engl. J. Med."},{"key":"996_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-025-00962-1","author":"D Barnes","year":"2025","unstructured":"Barnes, D., Ladeira, L. & Masereeuw, R. From big data to smart decisions: artificial intelligence in kidney risk assessment. Nat. Rev. Nephrol. https:\/\/doi.org\/10.1038\/s41581-025-00962-1 (2025).","journal-title":"Nat. Rev. Nephrol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00996-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00996-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T12:04:42Z","timestamp":1760616282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-025-00996-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["996"],"URL":"https:\/\/doi.org\/10.1038\/s41581-025-00996-5","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"31 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"H.-J.A. has received lecture and consultancy fees from GSL, Novartis, AstraZeneca, Roche, Bayer, Boehringer-Ingelheim, SOBI, Otsuka and CSL Vifor. He receives payments for his role as Editor-in-Chief of Nephrology Dialysis Transplantation. Within the past 3 years, J.B. has received consultant and speaker fees from Kyowa Kirin, Alnylam, Novonordisk, Biocodex, Amgen, Alexion, Viatris and Amolyt, and research grants from Kyowa Kirin. D.W.J. has received consultancy fees, research grants, speaker\u2019s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca, Bayer, and AWAK, speaker\u2019s honoraria from ONO and Boehringer Ingelheim & Lilly, and travel sponsorships from Ono and Amgen. He is a current recipient of an Australian National Health and Medical Research Council Leadership Investigator Grant (APP1194485). K.S. has consulted for Otsuka, Pfizer, Vertex and ProKidney therapeutics and is a founder of Tarna Therapeutics. The Susztak laboratory receives funding from Regeneron, Genentech, Novartis, Boehringer Ingelheim, Gilead, Novo Nordisk, GSK and Calico. K.T. has received grants from Bayer and Travere for investigator-initiated research paid to her institution, has consulted for Eli Lilly and Company, Boehringer Ingelheim, Bayer, AstraZeneca, Novo Nordisk and ProKidney. M.Y. received research grants from Mitsubishi Tanabe Pharma and Boehringer Ingelheim, lecture honoraria from Astellas, AstraZeneca, Kyowa Kirin, Mitsubishi Tanabe Pharma Corporation and Chugai Pharmaceuticals, and is on the advisory board of AstraZeneca and Novartis. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}